TY - JOUR
T1 - Cytokine-induced killer cells are terminallydifferentiated activated CD8 cytotoxic T-EMRA lymphocytes
AU - Franceschetti, Marta
AU - Pievani, Alice
AU - Borleri, Gianmaria
AU - Vago, Luca
AU - Fleischhauer, Katharina
AU - Golay, Josée
AU - Introna, Martino
PY - 2009/5
Y1 - 2009/5
N2 - Objective: Cytokine-induced killer cells (CIK) are CD3+CD56+ T cells with natural killer (NK)-like cytotoxic activity used for the immunotherapy of tumors. We aimed to fully characterize CIK cells and define their ontogeny. Materials and Methods: CIK were generated in vitro by stimulation of peripheral blood mononuclear cells or T-cell subsets with interferon-γ, anti-CD3 and interleukin-2. They were fully characterized in terms of phenotype, cytotoxic activity, and gene expression with respect to circulating CD3+CD56+ cells, NK cells, and CD56- T cells present in CIK cultures. Results: We demonstrate that CIK are terminally differentiated CD8 T cells that derive from proliferating CD3+CD56-CD8+ T cells. They express polyclonal T-cell receptor Vβ chains and have acquired CD56, NKG2D, and large granular lymphocyte morphology, but lack expression of most NK-specific activating (NKp30, NKp44, NKp46) and inhibitory (KIR2DL1, KIR2DL2, KIR3DL1, NKG2A, CD94) receptors, and can kill K562 targets. Circulating CD3+CD56+ cells are also CD8+CD16-, but are oligoclonal, poorly cytotoxic for K562, and express lower levels of CD56 and NKG2D. Gene profiling of CIK, CD56- T and NK cells present at the end of culture shows that differences are much more limited between CIK and CD56- T compared to CIK and NK cells. Most of the genes upregulated in CIK cells compared to CD56- T cells are part of the tumor necrosis factor gene network. Conclusions: The CIK phenotype, that is CD45RA+, CCR7-, CD62L-weakly positive, CD11a+, CD27+, CD28-, macrophage inflammatory protein 1α+, perforin+, Fas ligand+ coincides almost exactly with that described for the T RA+ effector memory CD27 single positive subset of terminally differentiated human memory T cells.
AB - Objective: Cytokine-induced killer cells (CIK) are CD3+CD56+ T cells with natural killer (NK)-like cytotoxic activity used for the immunotherapy of tumors. We aimed to fully characterize CIK cells and define their ontogeny. Materials and Methods: CIK were generated in vitro by stimulation of peripheral blood mononuclear cells or T-cell subsets with interferon-γ, anti-CD3 and interleukin-2. They were fully characterized in terms of phenotype, cytotoxic activity, and gene expression with respect to circulating CD3+CD56+ cells, NK cells, and CD56- T cells present in CIK cultures. Results: We demonstrate that CIK are terminally differentiated CD8 T cells that derive from proliferating CD3+CD56-CD8+ T cells. They express polyclonal T-cell receptor Vβ chains and have acquired CD56, NKG2D, and large granular lymphocyte morphology, but lack expression of most NK-specific activating (NKp30, NKp44, NKp46) and inhibitory (KIR2DL1, KIR2DL2, KIR3DL1, NKG2A, CD94) receptors, and can kill K562 targets. Circulating CD3+CD56+ cells are also CD8+CD16-, but are oligoclonal, poorly cytotoxic for K562, and express lower levels of CD56 and NKG2D. Gene profiling of CIK, CD56- T and NK cells present at the end of culture shows that differences are much more limited between CIK and CD56- T compared to CIK and NK cells. Most of the genes upregulated in CIK cells compared to CD56- T cells are part of the tumor necrosis factor gene network. Conclusions: The CIK phenotype, that is CD45RA+, CCR7-, CD62L-weakly positive, CD11a+, CD27+, CD28-, macrophage inflammatory protein 1α+, perforin+, Fas ligand+ coincides almost exactly with that described for the T RA+ effector memory CD27 single positive subset of terminally differentiated human memory T cells.
UR - http://www.scopus.com/inward/record.url?scp=64249142143&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=64249142143&partnerID=8YFLogxK
U2 - 10.1016/j.exphem.2009.01.010
DO - 10.1016/j.exphem.2009.01.010
M3 - Article
C2 - 19375652
AN - SCOPUS:64249142143
VL - 37
JO - Experimental Hematology
JF - Experimental Hematology
SN - 0301-472X
IS - 5
ER -